Metraipolis › archive › dc_70a2b43d2f06

A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903) — Europe PMC PMID:42081056

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42081056
DOI
10.1007/s10120-[numero omesso]-w
License (as archived)
solo-consultazione
Archived
2026-10-06T10:53:03.029Z
SHA-256 of the archived text
eccbf57ce0dda6e9875c1d6fcd5390cb3e91360330ccf112c558ceb0f76a850c
Stable URL of this page
https://metraipolis.com/documento/dc_70a2b43d2f06

How to cite

A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903) — Europe PMC PMID:42081056 — Europe PMC (en), https://europepmc.org/article/MED/42081056 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_70a2b43d2f06 (Metraipolis archive dc_70a2b43d2f06, sha256 eccbf57ce0dda6e9875c1d6fcd5390cb3e91360330ccf112c558ceb0f76a850c)
BibTeX
@misc{dc70a2b43d2f06,
  title = {A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903) — Europe PMC PMID:42081056},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42081056},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_70a2b43d2f06; sha256 eccbf57ce0dda6e9875c1d6fcd5390cb3e91360330ccf112c558ceb0f76a850c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42081056. Agents can read the archived copy with the MCP tool read_document.